4883 — Modalis Therapeutics Income Statement
0.000.00%
Annual income statement for Modalis Therapeutics, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 645 | 342 | 1.1 | 40.5 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 487 | 740 | 757 | 2,815 | 2,409 |
Operating Profit | 157 | -398 | -756 | -2,775 | -2,409 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 146 | -440 | -745 | -2,707 | -2,391 |
Provision for Income Taxes | |||||
Net Income After Taxes | 141 | -448 | -739 | -2,703 | -2,392 |
Net Income Before Extraordinary Items | |||||
Net Income | 141 | -448 | -739 | -2,703 | -2,392 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 141 | -448 | -739 | -2,703 | -2,392 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 5.96 | -17 | -36.6 | -77 | -76.4 |
Dividends per Share |